Key Takeaways Semaglutide produces clinically significant weight loss the STEP 1 trial demonstrated a mean 14.9% body weight reduction at 68 weeks with the 2.4 mg dose The dose escalation schedule is medically necessary, not optional rushing it leads to severe GI side effects that cause most treatment discontinuations Semaglutide is a long-term medication weight returns if treatment is stopped, as shown in the STEP 1 extension trial It carries real contraindications including a family history of medullary thyroid carcinoma, MEN2, pregnancy, and severe GI disease Drug interactions with oral medications are clinically relevant your full medication list must be reviewed by a pharmacist or physician before starting Maximum benefit requires combining semaglutide with a healthy diet and physical activity it reduces appetite, but it does not replace lifestyle modification References Wilding JPH, Batterham RL, Calanna S, et al
Potential Interactions and What to Watch For While the general consensus is that antibiotics can be taken with Ozempic, there are important nuances and potential areas of interaction that both patients and healthcare providers need to monitor closely
Recent regulatory approvals for treatments like semaglutide (Wegovy) for obesity, in addition to diabetes, have broadened the patient base and further fueled market expansion
Packaged in eco-friendly, small-batch containers
